{"id":8153,"date":"2025-07-27T09:05:25","date_gmt":"2025-07-27T06:05:25","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8153"},"modified":"2025-07-27T09:05:25","modified_gmt":"2025-07-27T06:05:25","slug":"monoclonal-antibody-shows-promise-in-cardiogenic-shock","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/monoclonal-antibody-shows-promise-in-cardiogenic-shock\/","title":{"rendered":"Monoclonal Antibody Shows Promise in Cardiogenic Shock"},"content":{"rendered":"<div>Monoclonal Antibody Shows Promise in Cardiogenic Shock<\/div>\n<div><\/div>\n<div>Published: July 24, 2025 \u2013 Medscape<\/div>\n<div><\/div>\n<div>Key Notes:<\/div>\n<div><\/div>\n<div>1. New Treatment Tested<\/div>\n<div><span> \u2022 A monoclonal antibody called procizumab was tested for the first time in humans with cardiogenic shock.<\/span><\/div>\n<div><span> \u2022 The drug targets DPP3, an enzyme linked to high death rates in shock by disrupting heart and kidney function.<\/span><\/div>\n<div>2. Case Report in Germany<\/div>\n<div><span> \u2022 Three critically ill patients with septic and cardiogenic shock were treated under compassionate use.<\/span><\/div>\n<div><span> \u2022 All had high DPP3 levels and failed standard treatments.<\/span><\/div>\n<div><span> \u2022 After a single dose of procizumab, all 3 showed:<\/span><\/div>\n<div><span> \u2022 Lower need for norepinephrine<\/span><\/div>\n<div><span> \u2022 Better oxygen levels<\/span><\/div>\n<div><span> \u2022 Drop in DPP3 activity and lactate<\/span><\/div>\n<div>3. Outcomes<\/div>\n<div><span> \u2022 Only one patient survived and was discharged to rehab.<\/span><\/div>\n<div><span> \u2022 The other two died within two weeks from unrelated complications.<\/span><\/div>\n<div><span> \u2022 Still, the treatment showed rapid improvements in hemodynamics.<\/span><\/div>\n<div>4. Experts React<\/div>\n<div><span> \u2022 Experts called the findings \u201cimpressive but early.\u201d<\/span><\/div>\n<div><span> \u2022 The treatment is still experimental and needs larger trials (Phase 2 and 3) to confirm safety and benefit.<\/span><\/div>\n<div>5. What\u2019s Next?<\/div>\n<div><span> \u2022 A Phase 1b trial (PROCARD 1b) is underway, aiming to enroll 130 patients with cardiogenic shock and high DPP3.<\/span><\/div>\n<div><span> \u2022 Researchers believe careful patient selection based on DPP3 levels will be key to success.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.medscape.com\/viewarticle\/procizumab-cardiogenic-shock\">https:\/\/www.medscape.com\/viewarticle\/procizumab-cardiogenic-shock<\/a><\/div>\n<div><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Monoclonal Antibody Shows Promise in Cardiogenic Shock Published: July 24, 2025 \u2013 Medscape Key Notes: 1. New Treatment Tested \u2022 A monoclonal antibody called procizumab was tested for the first time in humans with cardiogenic shock. \u2022 The drug targets DPP3, an enzyme linked to high death rates in shock by disrupting heart and kidney [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8153","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8153"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8153\/revisions"}],"predecessor-version":[{"id":8154,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8153\/revisions\/8154"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}